334 related articles for article (PubMed ID: 26091546)
1. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
[TBL] [Abstract][Full Text] [Related]
2. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
[TBL] [Abstract][Full Text] [Related]
3. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Ali KF; Shukla AP; Aronne LJ
Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
[TBL] [Abstract][Full Text] [Related]
4. Practical Use of Pharmacotherapy for Obesity.
Igel LI; Kumar RB; Saunders KH; Aronne LJ
Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
Khalil H; Ellwood L; Lord H; Fernandez R
Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
[No Abstract] [Full Text] [Related]
6. Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
[No Abstract] [Full Text] [Related]
7. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
8. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone/bupropion for obesity.
Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
[TBL] [Abstract][Full Text] [Related]
10. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with naltrexone and bupropion for obesity.
Billes SK; Greenway FL
Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Greig SL; Keating GM
Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for obesity: What you need to know.
Bersoux S; Byun TH; Chaliki SS; Poole KG
Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
[TBL] [Abstract][Full Text] [Related]
14. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W; Trujillo JM; Megyeri J
Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
Drugs R D; 2010; 10(1):25-32. PubMed ID: 20509712
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Apovian CM
Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]